Checkpoint Inhibitors news and latest updates

imfinzi astrazeneca breakthrough designation

News and Trends 11 Sep 2017

UPDATE: AstraZeneca’s Checkpoint Inhibitor Could be a Lung Cancer Blockbuster

UPDATE: 11/09/2017: AstraZeneca has presented impressive results at ESMO that show Imfinzi adding 11 months to patient survival, or decreasing the risk of progression by 48%, in Stage 3 NSCLC. This indication represents a sizable market segment — about half of lung cancer — and Imfinzi’s first-line position could make it a blockbuster. Original Publication: […]

September 11, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 8 Sep 2017

Checkpoint Inhibitor from Regeneron and Sanofi gets Priority After Breakup

The FDA has granted breakthrough therapy designation to Regeneron and Sanofi for cemiplimab, just a month after announcing they will part ways soon. Cemiplimab (REGN2810) has been granted breakthrough therapy designation by the FDA for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), considered the second deadliest skin cancer after melanoma. The antibody is a […]

September 8, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Cancer immunotherapy resistance mechanism University Hospital Zurich

News and Trends 27 Jul 2017

Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism

Scientists from the University of Zurich have identified an epigenetic control switch responsible for turning melanoma unresponsive to immune checkpoint inhibitors. A study published this week in Cell Reports describes a mechanism that might be responsible for the development of resistance to cancer immunotherapy. The culprit turned out to be Ezh2, a protein that controls genetic […]

July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

astrazeneca imfinzi durvalumab tremelimumab

News and Trends 27 Jul 2017

AstraZeneca Misses Endpoint in Big Checkpoint Inhibitor Combo Trial

AstraZeneca has announced its Phase III trial with durvalumab and tremelimumab has failed to achieve better results than standard chemotherapy in lung cancer. AstraZeneca’s MYSTIC study was evaluating a combination of checkpoint inhibitors as a first-line treatment for metastatic non-small cell lung cancer. The therapy couldn’t improve progression-free survival when compared with the standard of care […]

July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 24 May 2017

Top Pharma eye British Tech to Predict Response to Checkpoint Inhibitors

Oxford BioDynamics will start the development of an epigenetic test to screen patients for a favorable response to anti-PD-L1 drugs. Oxford BioDynamics has announced an agreement with two of the top 10 global pharma to initiate the development of a blood-based test to predict the response to PD-L1 checkpoint inhibitors in patients with non-small cell […]

May 24, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Noxxon Merck checkpoint inhibitor combination

News and Trends 16 May 2017

Berlin Biotech Advances its Cancer Drug in a New Trial with Keytruda

Noxxon Pharma has teamed up with the NCT in Heidelberg to conduct a Phase I/II trial combining its lead NOX-A12 with checkpoint inhibitor Keytruda. Based in Berlin, Noxxon is yet another biotech looking to bolster the success of checkpoint inhibitors by combining them with its ‘next-generation’ immuno-oncology candidates. The company partnered up with Merck & Co. […]

May 16, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 10 May 2017

Roche’s Checkpoint Inhibitor Misfires in Late-Stage Trials

Roche’s drug tecentriq just failed a late-stage Phase III study in bladder cancer, raising questions about its future as an anticipated blockbuster. Roche and Genentech have been pushing their checkpoint inhibitor tecentriq onto the market last year, going for a number of different indications including bladder cancer and non-small cell lung cancer (NSCLC). After the FDA handed out accelerated approval in May 2016, […]

May 10, 2017 - 3 minutesmins - By Melanie De Almeida

Patrick Baeuerle Successful German Biotech Leader

Interview 17 Apr 2017

Meet One of the Most Successful German Biotech Leaders Ever

Patrick Baeuerle is the German biotech leader I wanted to interview the most (besides Simon Moroney from MorphoSys, who came to our Meetup in Munich last week). Patrick has explored and succeeded in just about every area of life sciences, be it as a highly cited academic researcher, a professor at Freiburg University, head of drug […]

April 17, 2017 - 6 minutesmins - By Philip Hemme

Heptares AstraZeneka AZD4635 checkpoint inhibitor

News and Trends 5 Apr 2017

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an €11M payment from AstraZeneca. Heptares has announced the wrap-up of its preclinical programme for a new checkpoint inhibitor, AZD4635 that reverses adenosine-mediated T cell suppression and enhances anti-tumor immunity. The British company will now receive an €11M ($12M) milestone payment from AstraZeneca, who obtained exclusive global rights […]

April 5, 2017 - 3 minutesmins - By Melanie De Almeida

Numab Ono Pharmaceutical Immuno Oncology

News and Trends 28 Mar 2017

Swiss Antibodies Recruited by the Developer of BMS’ Cancer Blockbuster

Ono Pharmaceutical is offering the Swiss Numab €241M (CHF 258M) for the development of a multi-specific antibody for immuno-oncology applications. Numab, one of the hottest biotechs in Zurich, has developed a unique technology to generate stable antibody fragments (not an easy feat!) and use them as building blocks for multi-specific antibodies that can target up […]

March 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

C7XeJ78WkAEE Ic 1.jpg large e1490029653662

Interview 20 Mar 2017

Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed

The unprecedented competition in the field represents a daunting challenge for companies trying to break in. A BIO-Europe Panel discussed remaining niches. BIO Europe’s panel on immuno-oncology was perhaps the most popular of the day, as attendees filled the room to hear the thoughts of John Haurum, CEO of F-star; Christophe Quéva, CSO of iTeos; and […]

March 20, 2017 - 3 minutesmins - By Evelyn Warner

Innate Pharma lirilumab leukemia failure

News and Trends 6 Feb 2017

French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial

Innate Pharma’s checkpoint inhibitor candidate lirilumab missed its primary endpoint in a Phase II trial, which gave a hard blow to the company’s stock. When the stock market opened this morning, Innate Pharma‘s stock went down by almost 25%. The company had just announced the results of a Phase II trial that failed to prove its […]

February 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Checkpoint Inhibitors

UPDATE: AstraZeneca’s Checkpoint Inhibitor Could be a Lung Cancer Blockbuster

Checkpoint Inhibitor from Regeneron and Sanofi gets Priority After Breakup

Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism

AstraZeneca Misses Endpoint in Big Checkpoint Inhibitor Combo Trial

Top Pharma eye British Tech to Predict Response to Checkpoint Inhibitors

Berlin Biotech Advances its Cancer Drug in a New Trial with Keytruda

Roche’s Checkpoint Inhibitor Misfires in Late-Stage Trials

Meet One of the Most Successful German Biotech Leaders Ever

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Swiss Antibodies Recruited by the Developer of BMS’ Cancer Blockbuster

Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed

French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!